Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Eur Urol Focus. 2021 Nov;7(6):1332-1338. doi: 10.1016/j.euf.2020.08.010. Epub 2020 Sep 19.
Stage-specific guideline recommendations are lacking for chemotherapy in micropapillary carcinoma of the urinary bladder (MCUB).
To test the efficacy of stage-specific chemotherapy for MCUB.
DESIGN, SETTING, AND PARTICIPANTS: Within the Surveillance, Epidemiology and End Results (SEER) registry (2001-2016), we identified patients with MCUB and pure urothelial carcinoma of the urinary bladder (UCUB) of all stages.
Kaplan-Meier survival analyses and multivariate Cox regression models were used to determine cancer-specific mortality (CSM) in addition to power analyses.
Of 210 491 patients of all stages, 518 (0.2%) harboured MCUB versus 209 973 (99.8%) UCUB. Stage at presentation was invariably higher in MCUB than in UCUB patients. Of the MCUB patients, 223 (43.1%) received chemotherapy versus 42 921 (20.4%) of the UCUB patients. In MCUB patients, chemotherapy improved CSM-free survival significantly in metastatic stage (hazard ratio [HR] 0.36, p = 0.04). Longer median CSM-free survival was also associated with chemotherapy use in addition to radical cystectomy (RC) versus RC alone in non-organ-confined MCUB (HR 0.69, p = 0.2). Additional power analyses revealed an underpowered comparison. Finally, no CSM difference was recorded in organ-confined MCUB according to the use of chemotherapy in addition to RC versus RC alone (HR 0.98, p = 1).
Stage at presentation was invariably higher in MCUB than in UCUB patients. Very important CSM reduction was associated with chemotherapy use in metastatic MCUB. A promising protective effect of perioperative chemotherapy might also be applicable to non-organ-confined MCUB, but without sufficient statistical power. Conversely, no association was recorded in organ-confined MCUB.
Patients with micropapillary carcinoma of the urinary bladder (MCUB) present in higher tumour stages than those with urothelial carcinoma of the urinary bladder. Chemotherapy for MCUB is effective in metastatic stages, but of no beneficial effect in organ-confined stage. In not-yet-metastatic but already non-organ-confined stages, we did not have enough observations to show a statistically significant protective effect of chemotherapy.
目前缺乏针对膀胱微乳头状癌(MCUB)的特定分期的化疗指南推荐。
测试针对 MCUB 的特定分期化疗的疗效。
设计、设置和参与者:我们在监测、流行病学和最终结果(SEER)登记处(2001-2016 年)中,确定了所有分期的 MCUB 患者和单纯膀胱尿路上皮癌(UCUB)患者。
采用 Kaplan-Meier 生存分析和多变量 Cox 回归模型来确定癌症特异性死亡率(CSM),并进行了功效分析。
在所有分期的 210491 例患者中,518 例(0.2%)为 MCUB,209973 例(99.8%)为 UCUB。与 UCUB 患者相比,MCUB 患者的分期始终更高。在 MCUB 患者中,223 例(43.1%)接受了化疗,而 42921 例(20.4%)UCUB 患者接受了化疗。在转移性分期中,化疗显著改善了 MCUB 患者的 CSM 无进展生存率(风险比[HR]0.36,p=0.04)。中位 CSM 无进展生存率的延长也与化疗联合根治性膀胱切除术(RC)而非单独 RC 相关,非器官受限 MCUB(HR0.69,p=0.2)。此外,根据化疗联合 RC 与单独 RC 相比,在器官受限 MCUB 中未记录到 CSM 差异(HR0.98,p=1)。
与 UCUB 患者相比,MCUB 患者的分期始终更高。在转移性 MCUB 中,与化疗相关的重要 CSM 降低。围手术期化疗的潜在保护作用可能也适用于非器官受限的 MCUB,但没有足够的统计学效力。相反,在器官受限的 MCUB 中未记录到相关性。
与膀胱尿路上皮癌患者相比,患有膀胱微乳头状癌的患者在肿瘤分期更高。MCUB 的化疗对转移性分期有效,但对器官受限的分期没有有益作用。在尚未转移但已非器官受限的阶段,我们没有足够的观察结果来显示化疗的统计学显著保护作用。